Combination Pill for Heart Failure Improved Heart Function, Symptoms and Quality of Life

Among patients with heart failure and reduced ejection fraction (HFrEF), those taking a "polypill" combination of three ...
FierceBiotech

New data show significant improvements in lung function using combination of tiotropium and olodaterol* in COPD patients

Ingelheim, Germany, 3rd September, 2012 – New phase II data presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that combining tiotropium with olodaterol ...
Science Daily

Major cystic fibrosis breakthrough made: Drug combination improves lung function

A major breakthrough to change the lives of cystic fibrosis sufferers. The trial looked at the treatment of patients with two copies of the F508DEL mutation which is carried by roughly half of all ...
Nature

Cardiac resynchronization therapy: does varying the pacing site or combination of sites improve cardiac function?

Patients with heart failure, serious atrioventricular nodal block and recurring atrial fibrillation who are treated with cardiac resynchronization therapy using traditional single-site ventricular ...
News Medical

Three-drug combination improves lung function, reduces symptoms in CF patients

A phase three clinical trial that UT Southwestern participated in determined that a three-drug combination improved lung function and reduced symptoms in cystic fibrosis (CF) patients who have a ...
Business Wire

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection ...

COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...
FierceBiotech

Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis Who ...

Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis Who Have Two Copies of the ...